Table 4 Abdominal pain and adverse event related to TACE procedure within 30 days after procedure

From: Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma

 

All patients ( n =177)

cTACE ( n =88)

DEB-TACE ( n =89)

P

Effect size

Post-procedural pain

85 (48.0%)

63 (71.6%)

22 (24.7%)

0.001

1.124

 Grade 1

47 (26.6%)

27 (30.7%)

20 (22.5%)

0.237

0.233

 Grade 2

22 (12.4%)

20 (22.7%)

2 (2.2%)

0.001

1.416

 Grade 3

16 (9.0%)

16 (18.2%)

0 (0.0%)

0.001

Nc

Fever

17 (9.6%)

10 (11.4%)

7 (7.9%)

0.457

0.224

 Grade 1

6 (3.4%)

5 (5.7%)

1 (1.1%)

0.118

0.933

 Grade 2

6 (3.4%)

4 (4.5%)

2 (2.2%)

0.444

0.408

 Grade 3

5 (2.8%)

1 (1.1%)

4 (4.5%)

0.243

0.784

Pain

15 (8.5%)

11 (12.5%)

4 (4.5%)

0.064

0.612

 Grade 1

5 (2.8%)

3 (3.4%)

2 (2.2%)

0.999

0.247

 Grade 2

6 (3.4%)

5 (5.7%)

1 (1.1%)

0.118

0.933

 Grade 3

4 (2.3%)

3 (3.4%)

1 (1.1%)

0.368

0.635

Fatigue

4 (2.3%)

4 (4.5%)

0 (0.0%)

0.059

Nc

 Grade 1

1 (0.6%)

1 (1.1%)

0 (0.0%)

0.497

Nc

 Grade 2

3 (1.7%)

3 (3.4%)

0 (0.0%)

0.121

Nc

Nausea/vomiting

5 (2.8%)

3 (3.4%)

2 (2.2%)

0.682

0.247

 Grade 2

5 (2.8%)

3 (3.4%)

2 (2.2%)

  

Haematoma

4 (2.3%)

3 (3.4%)

1 (1.1%)

0.368

0.635

 Grade 1

4 (2.3%)

3 (3.4%)

1 (1.1%)

  

Cholecystitis

3 (1.7%)

1 (1.1%)

2 (2.2%)

0.999

0.388

 Grade 2

2 (1.1%)

1 (1.1%)

1 (1.1%)

0.999

0.000

 Grade 3

1 (0.6%)

0 (0.0%)

1 (1.1%)

0.999

Nc

Necrosis (spleen infarction)

1 (0.6%)

0 (0.0%)

1 (1.1%)

0.999

Nc

 Grade 1

1 (0.6%)

0 (0.0%)

1 (1.1%)

  

Infection

1 (0.6%)

1 (1.1%)

0 (0.0%)

0.497

Nc

 Grade 5

1 (0.6%)

1 (1.1%)

0 (0.0%)

  

Allergic reaction

2 (1.1%)

1 (1.1%)

1 (1.1%)

0.999

 

 Grade 1

2 (1.1%)

1 (1.1%)

1 (1.1%)

 

0.000

Increased ALTa

3 (1.7%)

3 (3.4%)

0 (0.0%)

0.121

Nc

 Grade 1

2 (1.1%)

2 (2.3%)

0 (0.0%)

0.246

Nc

 Grade 2

1 (0.6%)

1 (1.1%)

0 (0.0%)

0.497

Nc

Liver abscess

2 (1.1%)

1 (1.1%)

1 (1.1%)

0.999

0.000

 Grade 2

2 (1.1%)

1 (1.1%)

1 (1.1%)

  

Liver function worseninga

6 (3.4%)

5 (5.7%)

1 (1.1%)

0.118

0.933

Other complications

7 (4.0%)

4 (4.5%)

3 (3.4%)

0.720

0.161

At least one severe AE

11 (6.2%)

5 (5.7%)

6 (6.7%)

0.999

0.095

  1. Abbreviations: AE=adverse event; ALT=alanine aminotransferase; cTACE=conventional transarterial chemoembolisation; DEB-TACE=drug-eluting beads transarterial chemoembolisation; Nc=not computable due to zero events in one class.
  2. aIncrease in Child-Pugh score of ⩾2 points.
Back to article page